Taiho Pharmaceutical (Otsuka)
Japanese oncology company behind futibatinib (Lytgobi) for bile duct cancer and the chemotherapy Lonsurf; acquired the ADC linker company Araris in 2025.
Futibatinib approved 2022 (FOENIX-CCA2); Lonsurf (trifluridine/tipiracil) in colorectal and gastric cancer; TAS-102 combinations; Araris Biotech acquisition (2025) for ADC platform.
Pages like this
not linked directly; found by shared links- TrialFOENIX-CCA2
Shares Futibatinib, Biliary tract cancer (cholangiocarcinoma).
- TermFGFR2 fusions and rearrangements
Shares Futibatinib, Biliary tract cancer (cholangiocarcinoma).
- IdeactDNA-guided switching among FGFR inhibitors
Shares Futibatinib, Biliary tract cancer (cholangiocarcinoma).
- InstitutionRamathibodi Hospital, Mahidol University
Shares Biliary tract cancer (cholangiocarcinoma), Colorectal cancer.
- InstitutionUSC Norris Comprehensive Cancer Center
Shares Myelodysplastic syndromes / neoplasms (MDS), Colorectal cancer.
- TermHepatectomy (liver resection)
Shares Biliary tract cancer (cholangiocarcinoma), Colorectal cancer.
- InstitutionZhongshan Hospital, Fudan University
Shares Biliary tract cancer (cholangiocarcinoma), Colorectal cancer.
- PersonTanios Bekaii-Saab
Shares Biliary tract cancer (cholangiocarcinoma), Colorectal cancer.